Not a good buy right now for an impatient trader: price is breaking below key support (below S1 7.805) with negative/expanding MACD momentum.
Despite very bullish Wall Street targets ($32–$33) and an attractive long-term story, near-term catalysts look limited (no fresh news this week; key data referenced for early 2026), which doesn’t fit a “need results now” approach.
Options flow is mixed but tilts defensive short-term (heavy put volume vs calls), reinforcing the idea to avoid chasing a bottom today.
Pre-market: 7.53 (-1.31%), trading below S1 (7.805) and near the next support band into S2 (7.099) → current tape is weak.
MACD histogram -0.179 and negatively expanding → bearish momentum increasing.
RSI(6) 31.2 → near-oversold, but not a confirmed reversal signal by itself.
Moving averages converging → no clear uptrend; consistent with a basing/weak trend rather than a confirmed turn.
Key levels: Support S2 ~7.10 (must-hold area); Resistance pivot ~8.95 then R1 ~10.09. A reclaim back above ~7.81 is the first step to reduce downside risk.
Options Data
Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio
Open interest put/call = 0.34 (calls dominate OI) → longer-horizon positioning looks more bullish.
Implied vol (30d) ~102% with IV percentile ~10 and IV rank ~4.7 → options are relatively cheap vs recent history (can also imply the market is not pricing an imminent catalyst).
Today’s option volume is elevated vs average (47.8%) and open interest is also elevated (111%) → rising attention, but directionally mixed (OI bullish skew, volume bearish skew).
Technical Summary
Sell
7
Buy
7
Positive Catalysts
Strong recent analyst support: multiple Overweight/Outperform reiterations and price target raises to ~$32–$33 tied to positive stiff person syndrome data.
Long-term upside narrative: potential regulatory/priority review angle noted by Wells Fargo given high unmet need.
Low IV percentile/rank: if bullish news emerges unexpectedly, options are not pricing extreme near-term movement relative to recent history.
Neutral/Negative Catalysts
with bearish MACD expansion increases probability of further drift toward ~7.10 support.
→ near-term traders are positioned defensively.
Financial Performance
Latest reported quarter: 2025/Q3.
Revenue: 0 (no commercial revenue yet).
Net loss: -$36.8M, improved ~6.65% YoY (loss narrowing modestly).
Overall: still a development-stage biotech profile with ongoing burn; fundamentals are not the near-term driver compared with clinical/regulatory catalysts.
Key changes: Morgan Stanley raised PT to $33 (from $25) and reiterated Overweight; Wells Fargo raised to $33 (from $31) Overweight; Leerink raised to $32 (from $25) Outperform.
Wall Street “pros” view: clinical data read-through seen as robust/transformative; meaningful unmet need supports premium upside scenarios.
Wall Street “cons” view (implied): timing/catalyst gap and development-stage financials keep the stock dependent on future data/regulatory progress.
Politicians/insiders/hedge funds: no notable recent insider or hedge fund trend; no recent congress trading data available.
Wall Street analysts forecast KYTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KYTX is 29.5 USD with a low forecast of 20 USD and a high forecast of 33 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast KYTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KYTX is 29.5 USD with a low forecast of 20 USD and a high forecast of 33 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.270
Low
20
Averages
29.5
High
33
Current: 7.270
Low
20
Averages
29.5
High
33
Wells Fargo
Overweight
maintain
$31 -> $33
AI Analysis
2025-12-16
Reason
Wells Fargo
Price Target
$31 -> $33
AI Analysis
2025-12-16
maintain
Overweight
Reason
Wells Fargo raised the firm's price target on Kyverna Therapeutics to $33 from $31 and keeps an Overweight rating on the shares. The firm notes that mivocabtagene-autoleucel's stiff person syndrome data is in line with its bull case and it believes shares should trade up into the mid-teens on the data. Wells thinks mivocabtagene-autoleucel could potentially benefit from priority review/CNPV given the high unmet need in stiff person syndrome.
Morgan Stanley
Michael Ulz
Overweight
maintain
$25 -> $33
2025-12-15
Reason
Morgan Stanley
Michael Ulz
Price Target
$25 -> $33
2025-12-15
maintain
Overweight
Reason
Morgan Stanley analyst Michael Ulz raised the firm's price target on Kyverna Therapeutics to $33 from $25 and keeps an Overweight rating on the shares. Top line data from the Phase 2 registrational study of mivocabtagene autoleucel in stiff person syndrome confirm robust, consistent activity and favorable tolerability, says the analyst, who views the results as "very positive."
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for KYTX
